MedTherapy Biotech Expands India Manufacturing Hub for Affordable CAR-T Cancer Therapy

Boston-based MedTherapy Biotech is accelerating its India operations with a gene therapy contract development and manufacturing organisation (CDMO) facility in Noida, aiming to reduce the cost and complexity of CAR-T cell therapies. The company, backed by Tata Sons, is preparing for clinical trials of a lymphoma-focused CAR-T treatment in India, with potential market approval by 2027 pending regulatory clearance.

Revolutionizing CAR-T Therapy with Low-Cost Manufacturing

CAR-T cell therapy, first approved in the U.S. By the FDA in 2017, has shown promise as a potential cure for certain cancers by genetically reprogramming a patient’s immune cells to target tumours. However, high manufacturing costs—often exceeding $500,000 per patient in the U.S.—and lengthy production times have limited global access. MedTherapy claims its technology could cut manufacturing costs by over 70% while reducing production timelines from weeks to just 20–24 hours.

“The current manufacturing crisis in the CAR-T industry is a global challenge,” said Bikash Verma, CEO of MedTherapy. “Our platform aims to make these life-saving therapies more accessible by significantly lowering costs and streamlining production.”

India’s Role as a Biotech Manufacturing Hub

MedTherapy’s Noida facility, operational since 2020, is designed to handle therapy needs for approximately 5,000 patients annually. The company plans to expand with a second facility in Greater Noida, targeting a capacity of 50,000 patients. Verma highlighted India’s potential as a global manufacturing base for advanced gene therapies, citing its scientific talent pool and lower operating costs.

“India’s infrastructure and expertise position it to become a key player in cell and gene therapy production,” Verma added. “This could drive down costs for patients worldwide.”

Collaborations and Pipeline Development

MedTherapy is collaborating with Cipla on a lymphoma-focused CAR-T therapy, with Phase I trials already conducted in the U.S. Clinical trials in India are expected to advance in the coming years, with a projected launch around 2027. The company also operates as a CDMO, manufacturing viral vectors and CAR-T therapies for other biotech firms, while developing its own pipeline for lymphoma, multiple myeloma, and solid tumours.

Verma noted that MedTherapy has engaged with 22 organizations across India, the U.S., Canada, and Europe, including Harvard University. The company’s broader pipeline includes candidates for breast, lung, bone, and brain cancers, with a focus on making CAR-T a first-line treatment option.

Challenges and Future Prospects

Despite its ambitions, MedTherapy faces hurdles in scaling production and securing regulatory approvals. Verma acknowledged the need for additional funding to expand manufacturing capacity, though specific investment details were not disclosed. The company’s success will depend on navigating India’s regulatory landscape and demonstrating the efficacy of its cost-effective manufacturing model.

As global demand for CAR-T therapies grows, MedTherapy’s strategy to localize production in India could reshape access to these treatments. With its dual focus on CDMO services and proprietary therapies, the company aims to position itself as a leader in affordable, high-quality gene therapy solutions.

Learn more about MedTherapy Biotech